Matches in SemOpenAlex for { <https://semopenalex.org/work/W302352011> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W302352011 abstract "Background: The impact of transcatheter aortic valve replacement (TAVR) strategy, valve type (balloon-expandable Edwards (ES) valve or self-expanding Medtronic CoreValve (MCV)) and geographical differences (USA or Europe) on new permanent pacemaker (PPM) implantation is unclear. Similarly, the impact of PPM implantation on mortality after TAVR is unclear. We perform the first meta-analysis of incidence, clinical outcomes and factors influencing PPM implantation after TAVR.Methods and Results: A total of 93 non-overlapping studies including 37,836 patients reporting 30-day PPM implantation rates post-TAVR were included. Random-effects model was used to calculate pooled estimates and risk ratios, summarized in Table 1. MCV (n=8076) was associated with increased PPM implantation rates compared to ES valve (n=20,280) (22.5%, 95% CI 19.4-25.9% vs. 6.5%, 95% CI 5.7-7.4%, p < 0.01). Among patients undergoing ES valve implantation, transapical (TA) approach was associated with increased PPM implantation rates compared to transfemoral (TF) approach (9.1%, 95% CI 6.5-11.5% vs. 4.8%, 95% CI 2.9-7.4%; p=0.02). Among patients undergoing TAVR by TF approach, MCV implantation was associated with increased PPM rates, compared to ES valve (22.51%, 95% CI 18.7-25.9% vs. 4.8%, 95% CI 2.9-7.4%; p<0.01). PPM implantation rates associated with ES or MCV were not statistically different between US or European studies. Compared to patients not requiring PPM post-TAVR, the need for new PPM implantation was not associated with increased 30-day mortality (Risk-ratio 0.84 95% CI 0.61-1.15, p=0.27) or 1-year mortality (Risk-ratio 0.94 95% CI 0.74-1.19, p=0.60).Conclusions: PPM implantation is a frequent complication after TAVR. This is more commonly associated with MCV and TA approach for ES valve and is not influenced by geographical zones. Despite the high incidence of PPM implantation associated with TAVR, the need for new PPM does not influence 30-day or 1-year mortality. ![][1] [1]: /embed/graphic-1.gif" @default.
- W302352011 created "2016-06-24" @default.
- W302352011 creator A5012329439 @default.
- W302352011 creator A5037744445 @default.
- W302352011 creator A5038617990 @default.
- W302352011 creator A5044531608 @default.
- W302352011 creator A5050932029 @default.
- W302352011 creator A5065241590 @default.
- W302352011 creator A5066563877 @default.
- W302352011 creator A5076977377 @default.
- W302352011 date "2014-11-25" @default.
- W302352011 modified "2023-09-26" @default.
- W302352011 title "Abstract 19882: Incidence, Clinical Outcomes and Factors Influencing Permanent Pacemaker Implantation after Transcatheter Aortic Valve Replacement - A Meta-Analysis of 93 Studies including 37,836 Patients" @default.
- W302352011 hasPublicationYear "2014" @default.
- W302352011 type Work @default.
- W302352011 sameAs 302352011 @default.
- W302352011 citedByCount "0" @default.
- W302352011 crossrefType "journal-article" @default.
- W302352011 hasAuthorship W302352011A5012329439 @default.
- W302352011 hasAuthorship W302352011A5037744445 @default.
- W302352011 hasAuthorship W302352011A5038617990 @default.
- W302352011 hasAuthorship W302352011A5044531608 @default.
- W302352011 hasAuthorship W302352011A5050932029 @default.
- W302352011 hasAuthorship W302352011A5065241590 @default.
- W302352011 hasAuthorship W302352011A5066563877 @default.
- W302352011 hasAuthorship W302352011A5076977377 @default.
- W302352011 hasConcept C120665830 @default.
- W302352011 hasConcept C121332964 @default.
- W302352011 hasConcept C126322002 @default.
- W302352011 hasConcept C141071460 @default.
- W302352011 hasConcept C164705383 @default.
- W302352011 hasConcept C2780007028 @default.
- W302352011 hasConcept C2780026749 @default.
- W302352011 hasConcept C2780714102 @default.
- W302352011 hasConcept C3017863430 @default.
- W302352011 hasConcept C44249647 @default.
- W302352011 hasConcept C61511704 @default.
- W302352011 hasConcept C71924100 @default.
- W302352011 hasConceptScore W302352011C120665830 @default.
- W302352011 hasConceptScore W302352011C121332964 @default.
- W302352011 hasConceptScore W302352011C126322002 @default.
- W302352011 hasConceptScore W302352011C141071460 @default.
- W302352011 hasConceptScore W302352011C164705383 @default.
- W302352011 hasConceptScore W302352011C2780007028 @default.
- W302352011 hasConceptScore W302352011C2780026749 @default.
- W302352011 hasConceptScore W302352011C2780714102 @default.
- W302352011 hasConceptScore W302352011C3017863430 @default.
- W302352011 hasConceptScore W302352011C44249647 @default.
- W302352011 hasConceptScore W302352011C61511704 @default.
- W302352011 hasConceptScore W302352011C71924100 @default.
- W302352011 hasLocation W3023520111 @default.
- W302352011 hasOpenAccess W302352011 @default.
- W302352011 hasPrimaryLocation W3023520111 @default.
- W302352011 hasRelatedWork W107933927 @default.
- W302352011 hasRelatedWork W1999846636 @default.
- W302352011 hasRelatedWork W2388775540 @default.
- W302352011 hasRelatedWork W2527750741 @default.
- W302352011 hasRelatedWork W2551157276 @default.
- W302352011 hasRelatedWork W2766489639 @default.
- W302352011 hasRelatedWork W2884210606 @default.
- W302352011 hasRelatedWork W2902226459 @default.
- W302352011 hasRelatedWork W2903923511 @default.
- W302352011 hasRelatedWork W2993712310 @default.
- W302352011 hasRelatedWork W3005455248 @default.
- W302352011 hasRelatedWork W3020845242 @default.
- W302352011 hasRelatedWork W3081988420 @default.
- W302352011 hasRelatedWork W3082895088 @default.
- W302352011 hasRelatedWork W3093958921 @default.
- W302352011 hasRelatedWork W3094939467 @default.
- W302352011 hasRelatedWork W3136664485 @default.
- W302352011 hasRelatedWork W3171914190 @default.
- W302352011 hasRelatedWork W3193983459 @default.
- W302352011 hasRelatedWork W3206339649 @default.
- W302352011 hasVolume "130" @default.
- W302352011 isParatext "false" @default.
- W302352011 isRetracted "false" @default.
- W302352011 magId "302352011" @default.
- W302352011 workType "article" @default.
!["Background: The impact of transcatheter aortic valve replacement (TAVR) strategy, valve type (balloon-expandable Edwards (ES) valve or self-expanding Medtronic CoreValve (MCV)) and geographical differences (USA or Europe) on new permanent pacemaker (PPM) implantation is unclear. Similarly, the impact of PPM implantation on mortality after TAVR is unclear. We perform the first meta-analysis of incidence, clinical outcomes and factors influencing PPM implantation after TAVR.Methods and Results: A total of 93 non-overlapping studies including 37,836 patients reporting 30-day PPM implantation rates post-TAVR were included. Random-effects model was used to calculate pooled estimates and risk ratios, summarized in Table 1. MCV (n=8076) was associated with increased PPM implantation rates compared to ES valve (n=20,280) (22.5%, 95% CI 19.4-25.9% vs. 6.5%, 95% CI 5.7-7.4%, p < 0.01). Among patients undergoing ES valve implantation, transapical (TA) approach was associated with increased PPM implantation rates compared to transfemoral (TF) approach (9.1%, 95% CI 6.5-11.5% vs. 4.8%, 95% CI 2.9-7.4%; p=0.02). Among patients undergoing TAVR by TF approach, MCV implantation was associated with increased PPM rates, compared to ES valve (22.51%, 95% CI 18.7-25.9% vs. 4.8%, 95% CI 2.9-7.4%; p<0.01). PPM implantation rates associated with ES or MCV were not statistically different between US or European studies. Compared to patients not requiring PPM post-TAVR, the need for new PPM implantation was not associated with increased 30-day mortality (Risk-ratio 0.84 95% CI 0.61-1.15, p=0.27) or 1-year mortality (Risk-ratio 0.94 95% CI 0.74-1.19, p=0.60).Conclusions: PPM implantation is a frequent complication after TAVR. This is more commonly associated with MCV and TA approach for ES valve and is not influenced by geographical zones. Despite the high incidence of PPM implantation associated with TAVR, the need for new PPM does not influence 30-day or 1-year mortality. ![][1] [1]: /embed/graphic-1.gif"](?object=%22Background%3A%20The%20impact%20of%20transcatheter%20aortic%20valve%20replacement%20(TAVR)%20strategy%2C%20valve%20type%20(balloon-expandable%20Edwards%20(ES)%20valve%20or%20self-expanding%20Medtronic%20CoreValve%20(MCV))%20and%20geographical%20differences%20(USA%20or%20Europe)%20on%20new%20permanent%20pacemaker%20(PPM)%20implantation%20is%20unclear.%20Similarly%2C%20the%20impact%20of%20PPM%20implantation%20on%20mortality%20after%20TAVR%20is%20unclear.%20We%20perform%20the%20first%20meta-analysis%20of%20incidence%2C%20clinical%20outcomes%20and%20factors%20influencing%20PPM%20implantation%20after%20TAVR.Methods%20and%20Results%3A%20A%20total%20of%2093%20non-overlapping%20studies%20including%2037%2C836%20patients%20reporting%2030-day%20PPM%20implantation%20rates%20post-TAVR%20were%20included.%20Random-effects%20model%20was%20used%20to%20calculate%20pooled%20estimates%20and%20risk%20ratios%2C%20summarized%20in%20Table%201.%20MCV%20(n%3D8076)%20was%20associated%20with%20increased%20PPM%20implantation%20rates%20compared%20to%20ES%20valve%20(n%3D20%2C280)%20(22.5%25%2C%2095%25%20CI%2019.4-25.9%25%20vs.%206.5%25%2C%2095%25%20CI%205.7-7.4%25%2C%20p%20%3C%200.01).%20Among%20patients%20undergoing%20ES%20valve%20implantation%2C%20transapical%20(TA)%20approach%20was%20associated%20with%20increased%20PPM%20implantation%20rates%20compared%20to%20transfemoral%20(TF)%20approach%20(9.1%25%2C%2095%25%20CI%206.5-11.5%25%20vs.%204.8%25%2C%2095%25%20CI%202.9-7.4%25%3B%20p%3D0.02).%20Among%20patients%20undergoing%20TAVR%20by%20TF%20approach%2C%20MCV%20implantation%20was%20associated%20with%20increased%20PPM%20rates%2C%20compared%20to%20ES%20valve%20(22.51%25%2C%2095%25%20CI%2018.7-25.9%25%20vs.%204.8%25%2C%2095%25%20CI%202.9-7.4%25%3B%20p%3C0.01).%20PPM%20implantation%20rates%20associated%20with%20ES%20or%20MCV%20were%20not%20statistically%20different%20between%20US%20or%20European%20studies.%20Compared%20to%20patients%20not%20requiring%20PPM%20post-TAVR%2C%20the%20need%20for%20new%20PPM%20implantation%20was%20not%20associated%20with%20increased%2030-day%20mortality%20(Risk-ratio%200.84%2095%25%20CI%200.61-1.15%2C%20p%3D0.27)%20or%201-year%20mortality%20(Risk-ratio%200.94%2095%25%20CI%200.74-1.19%2C%20p%3D0.60).Conclusions%3A%20PPM%20implantation%20is%20a%20frequent%20complication%20after%20TAVR.%20This%20is%20more%20commonly%20associated%20with%20MCV%20and%20TA%20approach%20for%20ES%20valve%20and%20is%20not%20influenced%20by%20geographical%20zones.%20Despite%20the%20high%20incidence%20of%20PPM%20implantation%20associated%20with%20TAVR%2C%20the%20need%20for%20new%20PPM%20does%20not%20influence%2030-day%20or%201-year%20mortality.%20!%5B%5D%5B1%5D%20%5B1%5D%3A%20%2Fembed%2Fgraphic-1.gif%22){kind=link}